BD (Becton, Dickinson and Company) announced its third fiscal quarter 2026 results, revealing a strong financial performance that surpassed earlier projections for revenue, operational margin, and earnings per share. This quarter marks a pivotal moment as the first full period operating as 'New BD' following the spin-off of its Life Sciences division, demonstrating the enhanced growth potential of its re-focused portfolio. The company's success is attributed to widespread commercial momentum across its core growth segments, efficient operational strategies, and the expanding influence of its BD Excellence framework.
Key financial highlights include a total revenue of $4.98 billion, indicating a 4.4% increase on a foreign currency-neutral basis, and an adjusted diluted EPS of $3.23, which is a 4.9% rise from the previous year. The adjusted operating margin stood at 24.9%, albeit with a 130 basis point decrease due to tariff impacts and heightened investment. BD's strategic emphasis on commercial growth platforms, such as Medical Essentials, Connected Care, BioPharma Systems, and Interventional, has been instrumental in driving these positive outcomes. Notably, U.S. revenue climbed by 6.9%, fueled by strong demand in Medical Delivery Solutions and specimen management. The company also reported a significant increase in free cash flow, reaching $1.73 billion year-to-date, a 44.6% improvement, alongside substantial share repurchases, returning $3.1 billion to shareholders. Looking forward, BD has revised its full-year adjusted EPS guidance upwards to a range of $12.62 to $12.72, and expects revenue growth at the higher end of its low single-digit foreign currency-neutral forecast.
Despite this robust performance, BD acknowledges ongoing challenges, including the phased conclusion of Alaris remediation efforts, which will exert a 200 basis point headwind on fiscal 2027 revenues. Additionally, market dynamics in China and reduced demand for vaccine-related products continue to pressure the BioPharma Systems segment. The company is proactively addressing these headwinds through strategic pricing adjustments, ongoing productivity gains from the BD Excellence program, and targeted investments in high-growth, high-margin areas. Leadership remains committed to a disciplined capital allocation framework and aims to achieve a long-term net leverage target of 2.5x, reinforcing its dedication to sustainable growth and shareholder value.
BD's continued success hinges on its ability to adapt and innovate within a dynamic healthcare landscape. By prioritizing commercial excellence, fostering groundbreaking innovation, and maintaining operational efficiency, the company sets a strong example for sustained growth and positive impact on global health. This forward-thinking approach not only navigates current market complexities but also paves the way for future advancements, ensuring BD remains a vital force in medical technology.
